{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T20:57:34Z","timestamp":1791925054830,"version":"4.3.4"},"reference-count":106,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2015,4,23]],"date-time":"2015-04-23T00:00:00Z","timestamp":1429747200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Rheumatol Rep"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1007\/s11926-015-0513-4","type":"journal-article","created":{"date-parts":[[2015,4,22]],"date-time":"2015-04-22T04:24:58Z","timestamp":1429676698000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":53,"title":["The Prediction and Monitoring of Toxicity Associated with Long-Term Systemic Glucocorticoid Therapy"],"prefix":"10.1007","volume":"17","author":[{"given":"Emma","family":"Harris","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Tiganescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandy","family":"Tubeuf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah Louise","family":"Mackie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,4,23]]},"reference":[{"issue":"6634","key":"513_CR1","first-page":"483","volume":"2","author":"P Hench","year":"1950","unstructured":"Hench P. Effects of cortisone in the rheumatic diseases. Lancet. 1950;2(6634):483\u20134.","journal-title":"Lancet"},{"key":"513_CR2","doi-asserted-by":"crossref","unstructured":"Smolen, J.S., et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. 2014;73(3):492\u2013509.","DOI":"10.1136\/annrheumdis-2013-204573"},{"issue":"10","key":"513_CR3","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/j.clinthera.2011.09.009","volume":"33","author":"E Sarnes","year":"2011","unstructured":"Sarnes E et al. Incidence and US costs of corticosteroid-associated adverse events: a systematic literature review. Clin Ther. 2011;33(10):1413\u201332.","journal-title":"Clin Ther"},{"key":"513_CR4","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1745-6215-14-21","volume":"14","author":"JJ Kirkham","year":"2013","unstructured":"Kirkham JJ et al. Can a core outcome set improve the quality of systematic reviews?\u2014a survey of the Co-ordinating editors of Cochrane review groups. Trials. 2013;14:21.","journal-title":"Trials"},{"issue":"7","key":"513_CR5","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.jclinepi.2013.11.013","volume":"67","author":"M Boers","year":"2014","unstructured":"Boers M et al. Developing core outcome measurement sets for clinical trials: OMERACT filter 2.0. J Clin Epidemiol. 2014;67(7):745\u201353.","journal-title":"J Clin Epidemiol"},{"issue":"12","key":"513_CR6","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/j.jclinepi.2014.08.007","volume":"67","author":"YF Chen","year":"2014","unstructured":"Chen YF et al. Scientific hypotheses can be tested by comparing the effects of one treatment over many diseases in a systematic review. J Clin Epidemiol. 2014;67(12):1309\u201319.","journal-title":"J Clin Epidemiol"},{"issue":"6","key":"513_CR7","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1111\/j.1365-2133.1997.tb03929.x","volume":"136","author":"HM Sheu","year":"1997","unstructured":"Sheu HM et al. Depletion of stratum corneum intercellular lipid lamellae and barrier function abnormalities after long-term topical corticosteroids. Br J Dermatol. 1997;136(6):884\u201390.","journal-title":"Br J Dermatol"},{"issue":"6","key":"513_CR8","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1111\/j.0906-6705.2006.00435.x","volume":"15","author":"S Schoepe","year":"2006","unstructured":"Schoepe S et al. Glucocorticoid therapy-induced skin atrophy. Exp Dermatol. 2006;15(6):406\u201320.","journal-title":"Exp Dermatol"},{"issue":"9522","key":"513_CR9","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1016\/S0140-6736(06)68699-6","volume":"367","author":"J Newell-Price","year":"2006","unstructured":"Newell-Price J et al. Cushing\u2019s syndrome. Lancet. 2006;367(9522):1605\u201317.","journal-title":"Lancet"},{"issue":"1","key":"513_CR10","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0163-7258(02)00297-8","volume":"96","author":"H Sch\u00e4cke","year":"2002","unstructured":"Sch\u00e4cke H, D\u00f6cke W-D, Asadullah K. Mechanisms involved in the side effects of glucocorticoids. Pharmacol Ther. 2002;96(1):23\u201343.","journal-title":"Pharmacol Ther"},{"issue":"7","key":"513_CR11","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1172\/JCI64162","volume":"123","author":"A Tiganescu","year":"2013","unstructured":"Tiganescu A et al. 11\u03b2-Hydroxysteroid dehydrogenase blockade prevents age-induced skin structure and function defects. J Clin Invest. 2013;123(7):3051\u201360.","journal-title":"J Clin Invest"},{"issue":"2","key":"513_CR12","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1159\/000211022","volume":"5","author":"MJ Kerscher","year":"1992","unstructured":"Kerscher MJ, Korting HC. Comparative atrophogenicity potential of medium and highly potent topical glucocorticoids in cream and ointment according to ultrasound analysis. Skin Pharmacol. 1992;5(2):77\u201380.","journal-title":"Skin Pharmacol"},{"issue":"3","key":"513_CR13","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1002\/art.21984","volume":"55","author":"JR Curtis","year":"2006","unstructured":"Curtis JR et al. Population-based assessment of adverse events associated with long-term glucocorticoid use. Arthritis Care Res. 2006;55(3):420\u20136.","journal-title":"Arthritis Care Res"},{"issue":"3","key":"513_CR14","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1159\/000358009","volume":"228","author":"GR Vinding","year":"2014","unstructured":"Vinding GR et al. Self-reported skin morbidities and health-related quality of life: a population-based nested case-control study. Dermatology. 2014;228(3):261\u20138.","journal-title":"Dermatology"},{"issue":"11","key":"513_CR15","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1136\/ard.2009.124958","volume":"69","author":"MC Goes Van der","year":"2010","unstructured":"Van der Goes MC et al. Monitoring adverse events of low-dose glucocorticoid therapy: EULAR recommendations for clinical trials and daily practice. Ann Rheum Dis. 2010;69(11):1913\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"513_CR16","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S1081-1206(10)62989-4","volume":"80","author":"WW Storms","year":"1998","unstructured":"Storms WW, Theen C. Clinical adverse effects of inhaled corticosteroids: results of a questionnaire survey of asthma specialists. Ann Allergy Asthma Immunol. 1998;80(5):391\u20134.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"12","key":"513_CR17","doi-asserted-by":"crossref","first-page":"5587","DOI":"10.1210\/jc.2002-020048","volume":"87","author":"RC Andrews","year":"2002","unstructured":"Andrews RC et al. Abnormal cortisol metabolism and tissue sensitivity to cortisol in patients with glucose intolerance. J Clin Endocrinol Metab. 2002;87(12):5587\u201393.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"513_CR18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00441-013-1751-2","volume":"355","author":"F Quondamatteo","year":"2014","unstructured":"Quondamatteo F. Skin and diabetes mellitus: what do we know? Cell Tissue Res. 2014;355(1):1\u201321.","journal-title":"Cell Tissue Res"},{"key":"513_CR19","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1196\/annals.1404.027","volume":"1119","author":"E Makrantonaki","year":"2007","unstructured":"Makrantonaki E, Zouboulis CC. Molecular mechanisms of skin aging: state of the art. Ann N Y Acad Sci. 2007;1119:40\u201350.","journal-title":"Ann N Y Acad Sci"},{"issue":"10","key":"513_CR20","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1111\/j.1600-0625.2011.01335.x","volume":"20","author":"R Aschoff","year":"2011","unstructured":"Aschoff R et al. Evaluation of the atrophogenic potential of hydrocortisone 1\u00a0% cream and pimecrolimus 1\u00a0% cream in uninvolved forehead skin of patients with atopic dermatitis using optical coherence tomography. Exp Dermatol. 2011;20(10):832\u20136.","journal-title":"Exp Dermatol"},{"issue":"3","key":"513_CR21","doi-asserted-by":"crossref","first-page":"175","DOI":"10.4161\/derm.15065","volume":"3","author":"S Schoepe","year":"2011","unstructured":"Schoepe S, Schacke H, Asadullah K. Test systems for the determination of glucocorticoid receptor ligand induced skin atrophy. Dermatoendocrinol. 2011;3(3):175\u20139.","journal-title":"Dermatoendocrinol"},{"issue":"8","key":"513_CR22","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/s00403-014-1485-3","volume":"306","author":"H Norsgaard","year":"2014","unstructured":"Norsgaard H et al. Calcipotriol counteracts betamethasone-induced decrease in extracellular matrix components related to skin atrophy. Arch Dermatol Res. 2014;306(8):719\u201329.","journal-title":"Arch Dermatol Res"},{"issue":"5","key":"513_CR23","first-page":"1","volume":"19","author":"J Hooten","year":"2014","unstructured":"Hooten J, Hall 3rd R, Cardones A. Updates on the management of autoimmune blistering diseases. Skin Ther Lett. 2014;19(5):1\u20136.","journal-title":"Skin Ther Lett"},{"issue":"4","key":"513_CR24","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1111\/j.1476-5381.2009.00238.x","volume":"158","author":"H Schacke","year":"2009","unstructured":"Schacke H et al. Characterization of ZK 245186, a novel, selective glucocorticoid receptor agonist for the topical treatment of inflammatory skin diseases. Br J Pharmacol. 2009;158(4):1088\u2013103.","journal-title":"Br J Pharmacol"},{"issue":"6","key":"513_CR25","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1111\/j.1524-475X.2009.00543.x","volume":"17","author":"CK Sen","year":"2009","unstructured":"Sen CK et al. Human skin wounds: a major and snowballing threat to public health and the economy. Wound Repair Regen. 2009;17(6):763\u201371.","journal-title":"Wound Repair Regen"},{"issue":"5","key":"513_CR26","doi-asserted-by":"crossref","first-page":"H2144","DOI":"10.1152\/ajpheart.00591.2005","volume":"289","author":"PR Nagareddy","year":"2005","unstructured":"Nagareddy PR et al. Increased expression of iNOS is associated with endothelial dysfunction and impaired pressor responsiveness in streptozotocin-induced diabetes. Am J Physiol Heart Circ Physiol. 2005;289(5):H2144\u201352.","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"1","key":"513_CR27","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1089\/wound.2014.0546","volume":"4","author":"CJ Holmes","year":"2015","unstructured":"Holmes CJ et al. Dynamic role of host stress responses in modulating the cutaneous microbiome: implications for wound healing and infection. Adv Wound Care (New Rochelle). 2015;4(1):24\u201337.","journal-title":"Adv Wound Care (New Rochelle)"},{"issue":"3","key":"513_CR28","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1136\/ard.2005.038638","volume":"65","author":"JA Silva Da","year":"2006","unstructured":"Da Silva JA et al. Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data. Ann Rheum Dis. 2006;65(3):285\u201393. Epub 2005 Aug 17.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"513_CR29","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s00268-003-7397-6","volume":"28","author":"A Gosain","year":"2004","unstructured":"Gosain A, DiPietro LA. Aging and wound healing. World J Surg. 2004;28(3):321\u20136.","journal-title":"World J Surg"},{"issue":"4","key":"513_CR30","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.4049\/jimmunol.1201213","volume":"190","author":"AL Brubaker","year":"2013","unstructured":"Brubaker AL et al. Reduced neutrophil chemotaxis and infiltration contributes to delayed resolution of cutaneous wound infection with advanced age. J Immunol. 2013;190(4):1746\u201357.","journal-title":"J Immunol"},{"issue":"2","key":"513_CR31","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/0002-9343(94)90131-7","volume":"96","author":"KG Saag","year":"1994","unstructured":"Saag KG et al. Low dose long-term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events. Am J Med. 1994;96(2):115\u201323.","journal-title":"Am J Med"},{"issue":"6","key":"513_CR32","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1136\/ard.2009.114579","volume":"69","author":"MC Goes van der","year":"2010","unstructured":"van der Goes MC et al. Patient and rheumatologist perspectives on glucocorticoids: an exercise to improve the implementation of the European League Against Rheumatism (EULAR) recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis. 2010;69(6):1015\u201321.","journal-title":"Ann Rheum Dis"},{"issue":"610","key":"513_CR33","doi-asserted-by":"crossref","first-page":"e361","DOI":"10.3399\/bjgp13X667231","volume":"63","author":"T Helliwell","year":"2013","unstructured":"Helliwell T, Hider SL, Mallen CD. Polymyalgia rheumatica: diagnosis, prescribing, and monitoring in general practice. Br J Gen Pract. 2013;63(610):e361\u20136.","journal-title":"Br J Gen Pract"},{"issue":"7","key":"513_CR34","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1007\/s10067-013-2214-6","volume":"32","author":"L Carli","year":"2013","unstructured":"Carli L et al. Analysis of the prevalence of cataracts and glaucoma in systemic lupus erythematosus and evaluation of the rheumatologists\u2019 practice for the monitoring of glucocorticoid eye toxicity. Clin Rheumatol. 2013;32(7):1071\u20133.","journal-title":"Clin Rheumatol"},{"issue":"5","key":"513_CR35","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/j.1755-3768.2012.02444.x","volume":"91","author":"E Prokofyeva","year":"2013","unstructured":"Prokofyeva E, Wegener A, Zrenner E. Cataract prevalence and prevention in Europe: a literature review. Acta Ophthalmologica. 2013;91(5):395\u2013405.","journal-title":"Acta Ophthalmologica"},{"key":"513_CR36","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/1477-7525-4-74","volume":"4","author":"P Rasanen","year":"2006","unstructured":"Rasanen P et al. Cost-utility of routine cataract surgery. Health Qual Life Outcomes. 2006;4:74.","journal-title":"Health Qual Life Outcomes"},{"issue":"4","key":"513_CR37","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1159\/000329603","volume":"47","author":"E Prokofyeva","year":"2012","unstructured":"Prokofyeva E, Zrenner E. Epidemiology of major eye diseases leading to blindness in Europe: a literature review. Ophthalmic Res. 2012;47(4):171\u201388.","journal-title":"Ophthalmic Res"},{"issue":"7","key":"513_CR38","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1136\/ard.2008.092163","volume":"68","author":"D Huscher","year":"2009","unstructured":"Huscher D et al. Dose-related patterns of glucocorticoid-induced side effects. Ann Rheum Dis. 2009;68(7):1119\u201324.","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"513_CR39","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1136\/ard.2007.072157","volume":"66","author":"JN Hoes","year":"2007","unstructured":"Hoes JN et al. EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis. 2007;66(12):1560\u20137.","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"513_CR40","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1136\/ard.2009.117200","volume":"69","author":"M Mosca","year":"2010","unstructured":"Mosca M et al. European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies. Ann Rheum Dis. 2010;69(7):1269\u201374.","journal-title":"Ann Rheum Dis"},{"issue":"8089","key":"513_CR41","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/S0140-6736(78)92894-5","volume":"312","author":"RJM Lane","year":"1978","unstructured":"Lane RJM, Mastaglia FL. Drug-induced myopathies in man. Lancet. 1978;312(8089):562\u20136.","journal-title":"Lancet"},{"issue":"10","key":"513_CR42","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1016\/j.biocel.2013.05.036","volume":"45","author":"O Schakman","year":"2013","unstructured":"Schakman O et al. Glucocorticoid-induced skeletal muscle atrophy. Int J Biochem Cell Biol. 2013;45(10):2163\u201372.","journal-title":"Int J Biochem Cell Biol"},{"issue":"2","key":"513_CR43","doi-asserted-by":"crossref","first-page":"106","DOI":"10.7326\/0003-4819-134-2-200101160-00010","volume":"134","author":"JA Jover","year":"2001","unstructured":"Jover JA et al. Combined treatment of giant-cell arteritis with methotrexate and prednisone, a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2001;134(2):106\u201314.","journal-title":"Ann Intern Med"},{"issue":"10","key":"513_CR44","doi-asserted-by":"crossref","first-page":"3310","DOI":"10.1002\/art.22163","volume":"54","author":"M Mazlumzadeh","year":"2006","unstructured":"Mazlumzadeh M et al. Treatment of giant cell arteritis using induction therapy with high-dose glucocorticoids: a double-blind, placebo-controlled, randomized prospective clinical trial. Arthritis Rheum. 2006;54(10):3310\u20138.","journal-title":"Arthritis Rheum"},{"issue":"5","key":"513_CR45","first-page":"495","volume":"19","author":"RF Spiera","year":"2001","unstructured":"Spiera RF et al. A prospective, double-blind, randomized, placebo controlled trial of methotrexate in the treatment of giant cell arteritis (GCA). Clin Exp Rheumatol. 2001;19(5):495\u2013501.","journal-title":"Clin Exp Rheumatol"},{"issue":"10","key":"513_CR46","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1002\/art.1780401022","volume":"40","author":"SE Gabriel","year":"1997","unstructured":"Gabriel SE et al. Adverse outcomes of antiinflammatory therapy among patients with polymyalgia rheumatica. Arthritis Rheum. 1997;40(10):1873\u20138.","journal-title":"Arthritis Rheum"},{"issue":"2","key":"513_CR47","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/j.1365-2265.1983.tb03198.x","volume":"18","author":"AA Khaleeli","year":"1983","unstructured":"Khaleeli AA et al. Corticosteroid myopathy: a clinical and pathological study. Clin Endocrinol. 1983;18(2):155\u201366.","journal-title":"Clin Endocrinol"},{"issue":"1\u20132","key":"513_CR48","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.jns.2013.12.023","volume":"338","author":"OS Levin","year":"2014","unstructured":"Levin OS et al. Steroid myopathy in patients with chronic respiratory diseases. J Neurol Sci. 2014;338(1\u20132):96\u2013101.","journal-title":"J Neurol Sci"},{"key":"513_CR49","doi-asserted-by":"crossref","unstructured":"Hosono, O., et al. Quantitative analysis of skeletal muscle mass in patients with rheumatic diseases under glucocorticoid therapy\u2014comparison among bioelectrical impedance analysis, computed tomography, and magnetic resonance imaging. Modern Rheumatology, 2014. 25(2):1\u20137.","DOI":"10.3109\/14397595.2014.935078"},{"issue":"5","key":"513_CR50","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1212\/WNL.48.5.1234","volume":"48","author":"TT Batchelor","year":"1997","unstructured":"Batchelor TT et al. Steroid myopathy in cancer patients. Neurology. 1997;48(5):1234\u20138.","journal-title":"Neurology"},{"issue":"1","key":"513_CR51","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jbspin.2010.02.025","volume":"78","author":"RMR Pereira","year":"2011","unstructured":"Pereira RMR, de Carvalho JF. Glucocorticoid-induced myopathy. Joint Bone Spine. 2011;78(1):41\u20134.","journal-title":"Joint Bone Spine"},{"issue":"2","key":"513_CR52","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1097\/00008483-199703000-00002","volume":"17","author":"TK LaPier","year":"1997","unstructured":"LaPier TK. Glucocorticoid-induced muscle atrophy. The role of exercise in treatment and prevention. J Cardpulm Rehabil. 1997;17(2):76\u201384.","journal-title":"J Cardpulm Rehabil"},{"issue":"1","key":"513_CR53","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1210\/jcem-61-1-83","volume":"61","author":"FF Horber","year":"1985","unstructured":"Horber FF et al. Evidence that prednisone-induced myopathy is reversed by physical training. J Clin Endocrinol Metab. 1985;61(1):83\u20138.","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"513_CR54","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1136\/ard.58.11.713","volume":"58","author":"M Hansen","year":"1999","unstructured":"Hansen M et al. A randomised trial of differentiated prednisolone treatment in active rheumatoid arthritis. Clinical benefits and skeletal side effects. Ann Rheum Dis. 1999;58(11):713\u20138.","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"513_CR55","doi-asserted-by":"crossref","first-page":"963","DOI":"10.7326\/0003-4819-119-10-199311150-00001","volume":"119","author":"RF Laan","year":"1993","unstructured":"Laan RF et al. Low-dose prednisone induces rapid reversible axial bone loss in patients with rheumatoid arthritis. A randomized, controlled study. Ann Intern Med. 1993;119(10):963\u20138.","journal-title":"Ann Intern Med"},{"issue":"2","key":"513_CR56","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s00198-012-2034-6","volume":"24","author":"M Nikitovic","year":"2013","unstructured":"Nikitovic M et al. Direct health-care costs attributed to hip fractures among seniors: a matched cohort study. Osteoporos Int. 2013;24(2):659\u201369.","journal-title":"Osteoporos Int"},{"key":"513_CR57","doi-asserted-by":"crossref","unstructured":"Rizzoli, R. and E. Biver, Glucocorticoid-induced osteoporosis: who to treat with what agent? Nat Rev Rheumatol, 2014.","DOI":"10.1038\/nrrheum.2014.188"},{"key":"513_CR58","doi-asserted-by":"crossref","unstructured":"Compston J et al. Diagnosis and management of osteoporosis in postmenopausal women and older men in the UK: National Osteoporosis Guideline Group (NOGG) update 2013. Maturitas. 2013;75(4):392\u20136. Provides guidelines for the management of osteoporosis.","DOI":"10.1016\/j.maturitas.2013.05.013"},{"issue":"11","key":"513_CR59","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1002\/acr.20295","volume":"62","author":"JM Grossman","year":"2010","unstructured":"Grossman JM et al. American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res. 2010;62(11):1515\u201326.","journal-title":"Arthritis Care Res"},{"issue":"1","key":"513_CR60","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1056\/NEJMcp1012926","volume":"365","author":"RS Weinstein","year":"2011","unstructured":"Weinstein RS. Clinical practice. Glucocorticoid-induced bone disease. N Engl J Med. 2011;365(1):62\u201370.","journal-title":"N Engl J Med"},{"issue":"3","key":"513_CR61","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1359\/JBMR.041125","volume":"20","author":"FN Ton","year":"2005","unstructured":"Ton FN et al. Effects of low-dose prednisone on bone metabolism. J Bone Miner Res. 2005;20(3):464\u201370.","journal-title":"J Bone Miner Res"},{"issue":"3","key":"513_CR62","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s11926-011-0173-y","volume":"13","author":"D Uyl den","year":"2011","unstructured":"den Uyl D, Bultink IE, Lems WF. Advances in glucocorticoid-induced osteoporosis. Curr Rheumatol Rep. 2011;13(3):233\u201340.","journal-title":"Curr Rheumatol Rep"},{"issue":"10","key":"513_CR63","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1210\/me.2009-0069","volume":"23","author":"LC Hofbauer","year":"2009","unstructured":"Hofbauer LC, Rauner M. Minireview: live and let die: molecular effects of glucocorticoids on bone cells. Mol Endocrinol. 2009;23(10):1525\u201331.","journal-title":"Mol Endocrinol"},{"issue":"3","key":"513_CR64","first-page":"e486","volume":"21","author":"JM Albaum","year":"2014","unstructured":"Albaum JM et al. Osteoporosis management among chronic glucocorticoid users: a systematic review. J Popul Ther Clin Pharmacol. 2014;21(3):e486\u2013504.","journal-title":"J Popul Ther Clin Pharmacol"},{"issue":"9","key":"513_CR65","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.tips.2013.07.003","volume":"34","author":"M Kadmiel","year":"2013","unstructured":"Kadmiel M, Cidlowski JA. Glucocorticoid receptor signaling in health and disease. Trends Pharmacol Sci. 2013;34(9):518\u201330.","journal-title":"Trends Pharmacol Sci"},{"issue":"11","key":"513_CR66","doi-asserted-by":"crossref","first-page":"748","DOI":"10.3949\/ccjm.78a.10180","volume":"78","author":"MC Lansang","year":"2011","unstructured":"Lansang MC, Hustak LK. Glucocorticoid-induced diabetes and adrenal suppression: how to detect and manage them. Cleve Clin J Med. 2011;78(11):748\u201356.","journal-title":"Cleve Clin J Med"},{"key":"513_CR67","doi-asserted-by":"crossref","unstructured":"Unizony, S., et al. Inpatient complications in patients with giant cell arteritis: decreased mortality and increased risk of thromboembolism, delirium and adrenal insufficiency. Rheumatology (Oxford), 2015.","DOI":"10.1093\/rheumatology\/keu483"},{"issue":"7","key":"513_CR68","doi-asserted-by":"crossref","first-page":"e68713","DOI":"10.1371\/journal.pone.0068713","volume":"8","author":"Y Jamilloux","year":"2013","unstructured":"Jamilloux Y et al. Recovery of adrenal function after long-term glucocorticoid therapy for giant cell arteritis: a cohort study. PLoS ONE. 2013;8(7):e68713.","journal-title":"PLoS ONE"},{"issue":"5","key":"513_CR69","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1002\/art.21747","volume":"54","author":"JR Kirwan","year":"2006","unstructured":"Kirwan JR et al. The effect of therapeutic glucocorticoids on the adrenal response in a randomized controlled trial in patients with rheumatoid arthritis. Arthritis Rheum. 2006;54(5):1415\u201321.","journal-title":"Arthritis Rheum"},{"key":"513_CR70","doi-asserted-by":"crossref","unstructured":"Duru, N., et al. EULAR evidence-based and consensus-based recommendations on the management of medium to high-dose glucocorticoid therapy in rheumatic diseases. Annals of the Rheumatic Diseases, 2013: 1\u20139. Provides EULAR recommendations for managing patients on medium-high-dose glucocorticoid therapy.","DOI":"10.1136\/annrheumdis-2013-203249"},{"issue":"1","key":"513_CR71","doi-asserted-by":"crossref","first-page":"15","DOI":"10.5414\/CP201938","volume":"52","author":"E Gruvstad","year":"2014","unstructured":"Gruvstad E et al. Comparison of methods for evaluation of the suppressive effects of prednisolone on the HPA axis and bone turnover: changes in s-DHEAS are as sensitive as the ACTH test. Int J Clin Pharmacol Ther. 2014;52(1):15\u201326. doi: 10.5414\/CP201938 .","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"11","key":"513_CR72","doi-asserted-by":"crossref","first-page":"4245","DOI":"10.1210\/jc.2008-0710","volume":"93","author":"R Kazlauskaite","year":"2008","unstructured":"Kazlauskaite R et al. Corticotropin tests for hypothalamic-pituitary-adrenal insufficiency: a metaanalysis. J Clin Endocrinol Metab. 2008;93(11):4245\u201353.","journal-title":"J Clin Endocrinol Metab"},{"key":"513_CR73","doi-asserted-by":"crossref","unstructured":"Liu D et al. A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. Allergy Asthma Clin Immunol. 2013;9(1):30. Provides practical guidance for clinicians for monitoring and managing glucocorticoid-related adverse effects.","DOI":"10.1186\/1710-1492-9-30"},{"issue":"11","key":"513_CR74","doi-asserted-by":"crossref","first-page":"3854","DOI":"10.1172\/JCI66180","volume":"122","author":"HA Ferris","year":"2012","unstructured":"Ferris HA, Kahn CR. New mechanisms of glucocorticoid-induced insulin resistance: make no bones about it. J Clin Invest. 2012;122(11):3854\u20137.","journal-title":"J Clin Invest"},{"issue":"12","key":"513_CR75","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.tem.2011.09.001","volume":"22","author":"G Mazziotti","year":"2011","unstructured":"Mazziotti G, Gazzaruso C, Giustina A. Diabetes in Cushing syndrome: basic and clinical aspects. Trends Endocrinol Metab. 2011;22(12):499\u2013506.","journal-title":"Trends Endocrinol Metab"},{"key":"513_CR76","doi-asserted-by":"crossref","unstructured":"Nwaneri, C., H. Cooper, and D. Bowen-Jones, Mortality in type 2 diabetes mellitus: magnitude of the evidence from a systematic review and meta-analysis. The British Journal of Diabetes & Vascular Disease, 2013.","DOI":"10.1177\/1474651413495703"},{"issue":"11","key":"513_CR77","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.1002\/art.21421","volume":"52","author":"S Wassenberg","year":"2005","unstructured":"Wassenberg S et al. Very low-dose prednisolone in early rheumatoid arthritis retards radiographic progression over two years: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum. 2005;52(11):3371\u201380.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"513_CR78","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-136-1-200201010-00006","volume":"136","author":"AA Everdingen van","year":"2002","unstructured":"van Everdingen AA et al. Low-dose prednisone therapy for patients with early active rheumatoid arthritis: clinical efficacy, disease-modifying properties, and side effects: a randomized, double-blind, placebo-controlled clinical trial. Ann Intern Med. 2002;136(1):1\u201312.","journal-title":"Ann Intern Med"},{"issue":"10","key":"513_CR79","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1177\/0961203311402246","volume":"20","author":"Y Ha","year":"2011","unstructured":"Ha Y et al. Glucocorticoid-induced diabetes mellitus in patients with systemic lupus erythematosus treated with high-dose glucocorticoid therapy. Lupus. 2011;20(10):1027\u201334.","journal-title":"Lupus"},{"issue":"1","key":"513_CR80","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1093\/rheumatology\/kep303a","volume":"49","author":"B Dasgupta","year":"2010","unstructured":"Dasgupta B et al. BSR and BHPR guidelines for the management of polymyalgia rheumatica. Rheumatology (Oxford). 2010;49(1):186\u201390.","journal-title":"Rheumatology (Oxford)"},{"issue":"8","key":"513_CR81","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1093\/rheumatology\/keq039a","volume":"49","author":"B Dasgupta","year":"2010","unstructured":"Dasgupta B et al. BSR and BHPR guidelines for the management of giant cell arteritis. Rheumatology (Oxford). 2010;49(8):1594\u20137.","journal-title":"Rheumatology (Oxford)"},{"issue":"13","key":"513_CR82","doi-asserted-by":"crossref","first-page":"E495","DOI":"10.1503\/cmaj.140266","volume":"186","author":"AT Hancock","year":"2014","unstructured":"Hancock AT et al. Risk of vascular events in patients with polymyalgia rheumatica. CMAJ. 2014;186(13):E495\u2013501.","journal-title":"CMAJ"},{"issue":"4","key":"513_CR83","first-page":"737","volume":"29","author":"A Uddhammar","year":"2002","unstructured":"Uddhammar A et al. Increased mortality due to cardiovascular disease in patients with giant cell arteritis in northern Sweden. J Rheumatol. 2002;29(4):737\u201342.","journal-title":"J Rheumatol"},{"issue":"1","key":"513_CR84","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1093\/rheumatology\/kes353","volume":"52","author":"JA Avi\u00f1a-Zubieta","year":"2013","unstructured":"Avi\u00f1a-Zubieta JA et al. Immediate and past cumulative effects of oral glucocorticoids on the risk of acute myocardial infarction in rheumatoid arthritis: a population-based study. Rheumatology. 2013;52(1):68\u201375.","journal-title":"Rheumatology"},{"issue":"3","key":"513_CR85","doi-asserted-by":"crossref","first-page":"552","DOI":"10.3899\/jrheum.110851","volume":"39","author":"M Mazzantini","year":"2012","unstructured":"Mazzantini M et al. Adverse events during long-term low-dose glucocorticoid treatment of polymyalgia rheumatica: a retrospective study. J Rheumatol. 2012;39(3):552\u20137.","journal-title":"J Rheumatol"},{"issue":"9","key":"513_CR86","first-page":"1810","volume":"34","author":"I Hafstr\u00f6m","year":"2007","unstructured":"Hafstr\u00f6m I et al. Effects of low-dose prednisolone on endothelial function, atherosclerosis, and traditional risk factors for atherosclerosis in patients with rheumatoid arthritis\u2014a randomized study. J Rheumatol. 2007;34(9):1810\u20136.","journal-title":"J Rheumatol"},{"issue":"3","key":"513_CR87","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/eci.12227","volume":"44","author":"F Hafner","year":"2014","unstructured":"Hafner F et al. Endothelial function and carotid intima-media thickness in giant-cell arteritis. Eur J Clin Investig. 2014;44(3):249\u201356.","journal-title":"Eur J Clin Investig"},{"issue":"8","key":"513_CR88","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1136\/hrt.2003.020180","volume":"90","author":"PC Souverein","year":"2004","unstructured":"Souverein PC et al. Use of oral glucocorticoids and risk of cardiovascular and cerebrovascular disease in a population based case-control study. Heart. 2004;90(8):859\u201365.","journal-title":"Heart"},{"issue":"2","key":"513_CR89","doi-asserted-by":"crossref","first-page":"73","DOI":"10.7326\/M12-3046","volume":"160","author":"G Tomasson","year":"2014","unstructured":"Tomasson G et al. Risk for cardiovascular disease early and late after a diagnosis of giant-cell arteritis: a cohort study. Ann Intern Med. 2014;160(2):73\u201380.","journal-title":"Ann Intern Med"},{"issue":"6","key":"513_CR90","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1136\/ard.2003.008573","volume":"63","author":"J Kirwan","year":"2004","unstructured":"Kirwan J et al. A randomised placebo controlled 12\u00a0week trial of budesonide and prednisolone in rheumatoid arthritis. Ann Rheum Dis. 2004;63(6):688\u201395.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"513_CR91","doi-asserted-by":"crossref","first-page":"329","DOI":"10.7326\/0003-4819-156-5-201203060-00004","volume":"156","author":"MF Bakker","year":"2012","unstructured":"Bakker MF et al. Low-dose prednisone inclusion in a methotrexate-based, tight control strategy for early rheumatoid arthritis: a randomized trial. Ann Intern Med. 2012;156(5):329\u201339.","journal-title":"Ann Intern Med"},{"issue":"12","key":"513_CR92","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1136\/ard.2008.100008","volume":"68","author":"JN Hoes","year":"2009","unstructured":"Hoes JN et al. Adverse events of low- to medium-dose oral glucocorticoids in inflammatory diseases: a meta-analysis. Ann Rheum Dis. 2009;68(12):1833\u20138.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"513_CR93","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1530\/EJE-12-0041","volume":"166","author":"RM Reynolds","year":"2012","unstructured":"Reynolds RM et al. Glucocorticoid treatment and impaired mood, memory and metabolism in people with diabetes: the Edinburgh type 2 diabetes study. Eur J Endocrinol. 2012;166(5):861\u20138.","journal-title":"Eur J Endocrinol"},{"issue":"10","key":"513_CR94","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.4065\/81.10.1361","volume":"81","author":"TP Warrington","year":"2006","unstructured":"Warrington TP, Bostwick JM. Psychiatric adverse effects of corticosteroids. Mayo Clin Proc. 2006;81(10):1361\u20137.","journal-title":"Mayo Clin Proc"},{"issue":"10","key":"513_CR95","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.3899\/jrheum.101254","volume":"38","author":"J Ninan","year":"2011","unstructured":"Ninan J et al. Mortality in patients with biopsy-proven giant cell arteritis: a south Australian population-based study. J Rheumatol. 2011;38(10):2215\u20137.","journal-title":"J Rheumatol"},{"issue":"2","key":"513_CR96","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1161\/CIRCRESAHA.114.301374","volume":"114","author":"S Nadkarni","year":"2014","unstructured":"Nadkarni S et al. Investigational analysis reveals a potential role for neutrophils in giant-cell arteritis disease progression. Circ Res. 2014;114(2):242\u20138.","journal-title":"Circ Res"},{"issue":"11","key":"513_CR97","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1097\/00005650-199711000-00002","volume":"35","author":"P Dolan","year":"1997","unstructured":"Dolan P. Modeling valuations for EuroQol health states. Med Care. 1997;35(11):1095\u2013108.","journal-title":"Med Care"},{"issue":"2","key":"513_CR98","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0167-6296(01)00130-8","volume":"21","author":"J Brazier","year":"2002","unstructured":"Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure of health from the SF-36. J Health Econ. 2002;21(2):271\u201392.","journal-title":"J Health Econ"},{"issue":"4","key":"513_CR99","first-page":"592","volume":"35","author":"MJ Harrison","year":"2008","unstructured":"Harrison MJ et al. The validity and responsiveness of generic utility measures in rheumatoid arthritis: a review. J Rheumatol. 2008;35(4):592\u2013602.","journal-title":"J Rheumatol"},{"issue":"6","key":"513_CR100","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1002\/acr.21619","volume":"64","author":"L Buitinga","year":"2012","unstructured":"Buitinga L et al. Comparative responsiveness of the EuroQol-5D and short form 6D to improvement in patients with rheumatoid arthritis treated with tumor necrosis factor blockers: results of the Dutch Rheumatoid Arthritis Monitoring registry. Arthritis Care Res. 2012;64(6):826\u201332.","journal-title":"Arthritis Care Res"},{"issue":"9","key":"513_CR101","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1136\/annrheumdis-2011-200891","volume":"71","author":"C Gaujoux-Viala","year":"2012","unstructured":"Gaujoux-Viala C et al. Responsiveness of EQ-5D and SF-6D in patients with early arthritis: results from the ESPOIR cohort. Ann Rheum Dis. 2012;71(9):1478\u201383.","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"513_CR102","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1016\/j.socscimed.2004.08.034","volume":"60","author":"CA Marra","year":"2005","unstructured":"Marra CA et al. A comparison of generic, indirect utility measures (the HUI2, HUI3, SF-6D, and the EQ-5D) and disease-specific instruments (the RAQoL and the HAQ) in rheumatoid arthritis. Soc Sci Med. 2005;60(7):1571\u201382.","journal-title":"Soc Sci Med"},{"key":"513_CR103","doi-asserted-by":"crossref","unstructured":"Moller A, Sartipy U. Long-term health-related quality of life following surgery for lung cancer. Eur J Cardiothorac Surg. 2012;41(2):362\u20137. Demonstrates EQ-5D is responsive to AEs.","DOI":"10.1016\/j.ejcts.2011.05.055"},{"issue":"2","key":"513_CR104","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/hec.1580","volume":"19","author":"J Brazier","year":"2010","unstructured":"Brazier J, Tsuchiya A. Preference-based condition-specific measures of health: what happens to cross programme comparability? Health Econ. 2010;19(2):125\u20139.","journal-title":"Health Econ"},{"key":"513_CR105","unstructured":"NICE, Guide to the methods of technology appraisal 2013. Process and methods guides. 2013: London, UK."},{"issue":"2","key":"513_CR106","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s40273-013-0120-z","volume":"32","author":"EM Heather","year":"2014","unstructured":"Heather EM et al. Including adverse drug events in economic evaluations of anti-tumour necrosis factor-alpha drugs for adult rheumatoid arthritis: a systematic review of economic decision analytic models. Pharmacoeconomics. 2014;32(2):109\u201334.","journal-title":"Pharmacoeconomics"}],"container-title":["Current Rheumatology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-015-0513-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11926-015-0513-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-015-0513-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,23]],"date-time":"2019-08-23T18:54:15Z","timestamp":1566586455000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11926-015-0513-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4,23]]},"references-count":106,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["513"],"URL":"https:\/\/doi.org\/10.1007\/s11926-015-0513-4","relation":{},"ISSN":["1523-3774","1534-6307"],"issn-type":[{"value":"1523-3774","type":"print"},{"value":"1534-6307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,4,23]]},"article-number":"38"}}